Biotech · Public company · South San Francisco, CA, US

Spruce Biosciences, Inc.

Ticker SPRB · SEC CIK 0001683553

Track this companyFree. Adds Spruce Biosciences, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials70 recruiting or active

Pipeline programs4From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline4

SPR001Phase 2 · Congenital Adrenal HyperplasiaClinicalTrials.gov · fetched Nov 12, 2026
TildacerfontPhase 2 · Congenital Adrenal HyperplasiaClinicalTrials.gov · fetched Nov 12, 2026
TildacerfontPhase 2 · Polycystic Ovary SyndromeClinicalTrials.gov · fetched Nov 12, 2026
Tralesinidase alfa (TA)Mucopolysaccharidosis Type IIIBClinicalTrials.gov · fetched Nov 12, 2026

A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal AndrogensPHASE2 · TERMINATED · started May 15, 2022ClinicalTrials.gov NCT05370521 · fetched Nov 12, 2026
A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAHPHASE2 · TERMINATED · started Dec 10, 2021ClinicalTrials.gov NCT05128942 · fetched Nov 12, 2026
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAHPHASE2 · TERMINATED · started Feb 22, 2021ClinicalTrials.gov NCT04544410 · fetched Nov 12, 2026
A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAHPHASE2 · TERMINATED · started Aug 26, 2020ClinicalTrials.gov NCT04457336 · fetched Nov 12, 2026
Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal HyperplasiaPHASE2 · COMPLETED · started Sep 6, 2018ClinicalTrials.gov NCT03687242 · fetched Nov 12, 2026
Study of SPR001 in Adults With Classic Congenital Adrenal HyperplasiaPHASE2 · COMPLETED · started Jul 12, 2017ClinicalTrials.gov NCT03257462 · fetched Nov 12, 2026
Early Access Treatment With Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B)AVAILABLEClinicalTrials.gov NCT07733856 · fetched Nov 12, 2026